• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·9776.T
Share

Sapporo Clinical Laboratory Inc. Stocks

¥ 330696128Last Updated 26.02.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

¥ 38.23M

¥ 330696128
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sapporo Clinical Laboratory Inc. operates dispensing pharmacies in Japan. The company offers clinical examination, pathological examination, and holter examination services. It provides food hygiene environmental inspection, including food/processed product, facility hygiene, and food handler inspection services; and radiation management services. In addition, the company develops, sells, and maintains software, such as SCAN clinical testing systems; and offers support services for opening new clinics. Further, it provides HiWeb21 inspection result inquiry services, as well as sells and maintains software relating to clinical testing. The company was incorporated in 1965 and is based in Sapporo, Japan.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'c

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.07.2026 23:35

HSBC does not expect SpaceX's stock to rise. To value the stock, it had to abandon conventional methods.

24.07.2026 23:10

Freedom recommended buying Alphabet stock after the pullback. What could hinder its growth?

24.07.2026 22:45

Key Developments in the Kazakh Market: The Stakes of the Oil War and Signals from the National Bank

24.07.2026 22:34

"The Divorce of the Century": SK CEO to Pay Ex-Wife $643 Million but Retain Control of SK Hynix

24.07.2026 22:34

"The Divorce of the Century": SK CEO to Pay Ex-Wife $643 Million but Retain Control of SK Hynix

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026